INmune Bio, Inc. Receives Health Canada "No Objection Letter" to Commence Clinical Trial of XPro1595 in Mild Alzheimer's Disease
Stock Information for INmune Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.